Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. (NASDAQ: CHRS) is a commercial-stage oncology company whose news flow is centered on its PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and a proprietary immuno-oncology pipeline. Company announcements frequently highlight clinical data, regulatory developments, financial results and strategic updates related to its antibody-based cancer therapies.
News about Coherus Oncology often covers LOQTORZI in nasopharyngeal carcinoma (NPC), including long-term survival data from the JUPITER-02 Phase 3 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic NPC. Releases also describe LOQTORZI’s approved indications in the United States and its role as the only FDA-approved and available treatment for recurrent, locally advanced or metastatic NPC across all patient subsets and lines of therapy.
Investors and clinicians following CHRS can expect regular updates on pipeline programs such as CHS-114 and casdozokitug. Coherus reports biomarker and proof-of-mechanism data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, in head and neck squamous cell carcinoma and other solid tumors, as well as clinical and translational findings for casdozokitug, a novel IL-27 antagonist in advanced solid tumors including hepatocellular carcinoma and non-small cell lung cancer.
The company’s news stream also includes quarterly financial results, business updates, participation in major healthcare and oncology conferences, and investor-focused events. These items provide context on revenue trends for LOQTORZI, research and development spending on its immuno-oncology programs, and corporate strategy.
For market participants tracking CHRS, the Coherus Oncology news page on Stock Titan aggregates these press releases and related coverage, offering a centralized view of clinical milestones, regulatory disclosures and financial communications that can influence perceptions of the company’s oncology franchise and pipeline progress.
Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.
Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.
Coherus Oncology (NASDAQ: CHRS) closed an underwritten public offering of 28,600,000 common shares at $1.75 per share on Feb 17, 2026, generating approximately $50.1 million gross proceeds before fees.
The company granted underwriters a 30-day option to purchase up to 4,290,000 additional shares for over-allotments. Proceeds will support commercialization of LOQTORZI, continued clinical programs, working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) priced an underwritten public offering of 28,600,000 common shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company granted a 30-day option for an additional 4,290,000 shares and expects closing on or about February 17, 2026.
Net proceeds are intended to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock on Feb 12, 2026.
Key points: Coherus will offer shares from its effective Form S-3 shelf (File No. 333-291520, filed Nov 13, 2025); underwriters have a 30-day option for up to 15% additional shares. Net proceeds are targeted to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes. The Offering is subject to market conditions and may not be completed as proposed.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Coherus Oncology (NASDAQ: CHRS) announced publication in Molecular Cancer Therapeutics describing preclinical and first-in-human biomarker data for investigational anti-CCR8 antibody tagmokitug (CHS-114).
Key findings: picomolar binding affinity, no off-target binding, selective depletion of CCR8+ regulatory T cells, high prevalence and density of CCR8 across many solid tumors, tumor regression in mouse models with enhanced activity when combined with anti-PD-1, and translational proof-of-mechanism showing selective CCR8+ Treg reductions in patients.
The publication supports ongoing clinical development of tagmokitug in combination with toripalimab across multiple solid tumor settings.
Coherus (NASDAQ: CHRS) reported six-year follow-up from the Phase 3 JUPITER-02 trial showing LOQTORZI (toripalimab-tpzi) plus gemcitabine and cisplatin achieved a median overall survival of 64.8 months vs 33.7 months for chemotherapy alone (31-month improvement; HR 0.62; 95% CI 0.45–0.85).
Results presented at ESMO Asia 2025 reinforce LOQTORZI plus chemotherapy as a first-line option for recurrent or metastatic nasopharyngeal carcinoma and summarize key safety findings including immune-mediated adverse events.
Coherus Oncology (NASDAQ: CHRS) reported multiomic biomarker data for CHS-114 from the Phase 1b dose expansion and safety arms in recurrent/metastatic HNSCC on Nov 7, 2025.
Key findings: CHS-114 selectively depleted intratumoral CCR8+ Tregs by 74% and reduced total FOXP3+ Tregs by 43%, while increasing intratumoral CD8+ T cells by 73% and raising the CD8+/CCR8+ Treg ratio 12-fold. Peripheral blood showed sustained CD8+ activation and proliferation with combination dosing. Safety was described as manageable; a partial response was observed in one refractory HNSCC patient. Data were presented at SITC 2025 (abstract #640) with the presentation on Nov 8, 2025.
Coherus Oncology (NASDAQ: CHRS) reported Q3 2025 results and a business update on Nov 6, 2025. LOQTORZI net revenue was $11.2M in Q3, up 12% QoQ and 92% YoY; total net revenue from continuing operations was $11.6M for the quarter. Cash, cash equivalents and marketable securities were $191.7M as of Sept 30, 2025. R&D spending rose to $27.3M in Q3 while SG&A declined to $24.9M. Net loss from continuing operations was $44.5M, or $(0.38) per share, with non-GAAP net loss of $38.9M. Pipeline progress includes expansion of CHS-114 into colorectal cancer and multiple 2026 readouts for CHS-114 and casdozokitug.